Description: ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
Home Page: ars-pharma.com
SPRY Technical Analysis
3525 Del Mar Heights Road
San Diego,
CA
92130
United States
Phone:
858 335 1300
Officers
| Name | Title |
|---|---|
| Mr. Richard Lowenthal M.B.A., M.S., MSMSEL | Founder, Pres, CEO & Director |
| Dr. Sarina Tanimoto M.B.A., M.D. | Co-Founder & Chief Medical Officer |
| Dr. Robert Bell Ph.D. | Co-Founder & Chief Science Officer |
| Ms. Kathleen D. Scott CPA | Chief Financial Officer |
| Mr. Brian T. Dorsey M.S. | SVP of Operations & Project Management |
| Mr. Daniel Relovsky | Sr. VP of Marketing |
| Mr. Harris Kaplan M.B.A., MBA | Exec. VP of Commercial Strategy |
| Mr. Eric Karas | Chief Commercial Officer |
| Mr. Justin Chakma | Chief Bus. Officer & Sec. |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 329.6943 |
| IPO Date: | 2020-12-04 |
| Fiscal Year End: | December |
| Full Time Employees: | 9 |